Stocklytics Platform
Asset logo for symbol VTRS
Viatris
VTRS60
$10.800.00%$0.00
S&P500
Asset logo for symbol VTRS
VTRS60

$10.80

0.00%

Income Statement (VTRS)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT$236.10M-$245.00M$440.60M$529.50M$543.70M
EBITDA$905.80M$541.30M$1.13B$1.17B$1.22B
gross Profit$1.45B$1.49B$1.50B$1.61B$1.69B
NET Income$94.80M-$326.40M$113.90M-$765.60M$331.60M
total Revenue$3.73B$3.79B$3.66B$3.82B$3.94B

Balance Sheet (VTRS)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt$15.74B$16.17B$16.94B$17.38B$17.06B
stockholders Equity$19.79B$19.52B$20.01B$20.46B$20.86B
total Assets$44.75B$45.33B$47.34B$47.68B$48.74B
total Debt$17.61B$17.09B$17.96B$18.37B$18.37B
total Liabilities$24.96B$25.81B$27.32B$27.21B$27.87B

Cash Flow (VTRS)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$1.63B-$847.90M-$425.60M-$926.10M-$97.60M
free Cash Flow$750.50M$320.30M$563.80M$278.50M$732.00M
investing Cash Flow-----$53.80M
operating Cash Flow$826.50M$379.10M$614.60M$479.40M$834.10M

Viatris (VTRS) Financials

Viatris Inc (VTRS) is a leading global pharmaceutical company that focuses on providing affordable, high-quality medicines to patients worldwide. The company's financials reflect its commitment to delivering value to its stockholders. Viatris' income statement shows its revenue and expenses over a specific period, providing insight into its financial performance. The company's EBIT (Earnings Before Interest and Taxes) is a measure of its operating profitability, indicating how much profit it generates from its core operations. Similarly, EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures Viatris' operating performance and excludes non-operating expenses. The company's gross profit represents its total revenue minus the cost of goods sold, showcasing its profitability before considering other expenses.
Viatris' net income from stockholders refers to the profit available to the company's stockholders after accounting for all expenses and taxes. It demonstrates how efficiently Viatris is utilizing its resources to generate profits. The company's total revenue represents the sum of all its income sources, including sales of its pharmaceutical products and other operating revenues. Viatris' balance sheet provides a snapshot of its financial position at a specific point in time. It includes assets such as cash equivalents, which are highly liquid assets that can be readily converted into cash. Net debt is the difference between a company's total debt and its cash and cash equivalents. Viatris' stockholders' equity signifies the amount of funding provided by its stockholders and reflects the company's financial health. The company's total assets represent its combined holdings, including cash, accounts receivable, inventories, and property. Total debt includes both short-term and long-term obligations that Viatris owes to creditors.
Viatris' total liabilities encompass all of its financial obligations, including both short-term and long-term liabilities. The company's cash flow statement breaks down its cash inflows and outflows, providing insights into its liquidity and financial health. Financing cash flow represents the cash generated or used by Viatris to fund its operations or repay debt through activities such as issuing or repurchasing stock and paying dividends. Free cash flow is the amount of cash remaining after deducting capital expenditures from operating cash flow and is an essential indicator of a company's financial strength. Investing cash flow shows the cash used for or generated from investments in assets such as property, plant, and equipment. Operating cash flow represents the cash generated or used in day-to-day operations, showcasing Viatris' ability to generate consistent cash flow.
add Viatris  to watchlist

Keep an eye on Viatris

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level